SunVax mRNA Therapeutics — Insights https://sunvax.x1000.ai/insights Plain-language notes on cell-type-specific LNP delivery, for wet-lab scientists choosing kits or reading vendor copy critically. Every article cited. en-us Fri, 22 May 2026 07:00:02 GMT How this site is built — every claim sourced, every datum graded https://sunvax.x1000.ai/insights/how-this-site-is-built https://sunvax.x1000.ai/insights/how-this-site-is-built Fri, 22 May 2026 00:00:00 GMT A short note on the discipline behind this site: every kit datum carries a source URL + evidence grade (A/B/C) + verified_at timestamp. What that means for buyers reading specs here vs reading marketing decks elsewhere. CATP: a 525-fold IL-12 result, and what it means for SV-Delivery™ buyers https://sunvax.x1000.ai/insights/catp-525-fold-il-12 https://sunvax.x1000.ai/insights/catp-525-fold-il-12 Sun, 17 May 2026 00:00:00 GMT A 2025 peer-reviewed paper from Yingzhong Li and colleagues shows a 525-fold intratumoral IL-12 amplification using SunVax LNPs to co-deliver self-amplifying mRNA. Here is what to make of the result if you are a buyer of SV-Delivery™ kits. Mouse cytokine results don't carry over: what Yingzhong's Q3 disclosure means for your experiment https://sunvax.x1000.ai/insights/mouse-cytokine-vs-human https://sunvax.x1000.ai/insights/mouse-cytokine-vs-human Sun, 17 May 2026 00:00:00 GMT In the Antibody Conference panel, Yingzhong Li disclosed that SunVax's current efficacy data uses mouse cytokine constructs — and that testing human cytokine constructs is the necessary next step. Here is what to do with that. In vivo CAR-T: where lentivirus, AAV, and LNP each fit https://sunvax.x1000.ai/insights/in-vivo-cart-landscape https://sunvax.x1000.ai/insights/in-vivo-cart-landscape Sat, 16 May 2026 00:00:00 GMT In vivo CAR-T is a 5-10 year race between viral vectors and non-viral LNPs. Here is the landscape, in plain language, with the trade-offs that matter when picking a delivery kit today. PDX is still mouse: reading the human in vivo evidence carefully https://sunvax.x1000.ai/insights/mouse-to-human-translation https://sunvax.x1000.ai/insights/mouse-to-human-translation Sat, 16 May 2026 00:00:00 GMT SunVax reports 92-94% efficacy in PDX models. PDX is patient-derived xenograft — the tumor cells are human, but the immune system and circulating environment are mouse. Here is how to interpret that. Empirical screening, not ML, designs SV-Delivery™ kits https://sunvax.x1000.ai/insights/empirical-vs-ml-lnp https://sunvax.x1000.ai/insights/empirical-vs-ml-lnp Sat, 16 May 2026 00:00:00 GMT How SunVax explicitly chose an empirical-then-pattern workflow for LNP discovery, and why that matters for buyers reading "AI-driven" copy elsewhere.